Profound Medical Corp. Secures $36 Million in Registered Direct Offering to Fuel Commercial Expansion

Profound Medical Corp. announced the closing of its registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, generating gross proceeds of approximately $36 million before fees and expenses. The offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, acted as the exclusive placement agent for the offering. The company stated it intends to use the net proceeds to support expansion of sales and marketing activities, working capital, research and development, strategic transactions and general corporate purposes.

This capital infusion is significant for Profound Medical, a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer.

The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy. For more information on the company's technologies, visit https://profoundmedical.com/.

The successful $36 million offering provides Profound Medical with substantial resources to accelerate the commercialization of its innovative platforms. The funding is poised to enhance sales and marketing efforts critical for driving adoption of the TULSA Procedure in the competitive prostate disease treatment market. Furthermore, the capital supports ongoing research and development, which is essential for exploring new clinical applications for the Sonalleve platform and advancing the company's pipeline. This financial backing from healthcare-focused investors underscores confidence in Profound's technology and its potential to address significant unmet needs in minimally invasive therapeutic ablation. The offering's structure as a direct equity placement without warrants suggests a focused investment in the company's core growth trajectory, positioning Profound to expand its market presence and advance its mission of providing incision-free treatment options.